Emcure Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,363Cr
- +20.4% YoY
- +4.1% QoQ
- Net profit
- ₹231Cr
- +48.1% YoY
- −8% QoQ
- Margin
- 21%
- +3 pp YoY
- 0 pp QoQ
Guidance rank: #16 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years. Emcure aims for a low to mid-teens compounded annual revenue growth over the next 3 to 5 years, driven by both domestic and international markets.
From Emcure Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years.
- Domestic business is expected to grow in the high single-digits to low double digits, with Emcure targeting to outgrow the industry, driven by in-house R&D and strategic in-licensing.
- International markets (Europe and Canada) anticipate low-teens compounded growth, supported by strong ramp-up in products like Amphotericin B.
- Emerging markets, including ARV and non-ARV segments, are expected to grow at a healthy double-digit rate.
- Amphotericin B, recently launched in parts of Europe, offers significant growth potential across 23 countries with expected growth from next year onward.
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Emcure expects gross block additions of INR 300-400 crores per year over the next 2-3 years, excluding acquisitions.
- The company plans to maintain this capex intensity to support growth and capacity expansion.
- Focus on building strong in-house capacities, considered second only to innovators for certain high-volume products.
- Strategic investments include expanding manufacturing capacities at Sanand and Pune sites to service diverse markets.
- Emphasis on technology-driven R&D pipeline and collaborations, including partnerships with academia for biologics innovation.
2 more points from Emcure Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Emcure Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Emcure Pharmaceuticals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,363 | 1,963 | +20.4% | 2,270 | +4.1% |
| Operating profit (EBITDA) | 493 | 355 | +38.9% | 475 | +3.8% |
| Operating margin | 21% | 18% | +3 pp | 21% | 0 pp |
| Profit before tax | 314 | 230 | +36.5% | 341 | -7.9% |
| Net profit (PAT) | 231 | 156 | +48.1% | 251 | -8% |
| EPS (₹) | 12.16 | 8.11 | +49.9% | 12.84 | -5.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹325 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q3 FY26 results?
Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years. Emcure aims for a low to mid-teens compounded annual revenue growth over the next 3 to 5 years, driven by both domestic and international markets.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
Emcure expects gross block additions of INR 300-400 crores per year over the next 2-3 years, excluding acquisitions.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
